<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01146028</url>
  </required_header>
  <id_info>
    <org_study_id>01220</org_study_id>
    <nct_id>NCT01146028</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Tizanidine HCl Tablets 4 mg of Dr.Reddys Under Fasting Conditions</brief_title>
  <official_title>Randomized, 2-way Crossover, Bioequivalence Study of Tizanidine Hydrochloride 4mg Tablets and Zanaflex® 4mg Tablets Administered As 1 x 4mg Tablet in Healthy Adult Subjects Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this bioequivalence study is to compare the test Tizanidine Hydrochloride 4mg&#xD;
      tablets of Dr.Reddys Laboratories Limited with reference zanaflex® 4mg tablets of Elan in&#xD;
      healthy adult subjects under fasting conditions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized, 2-way crossover, bioequivalence study of Tizanidine Hydrochloride 4mg tablets and&#xD;
      zanaflex® 4mg tablets administered As 1 x 4mg tablet in healthy adult subjects under fasting&#xD;
      conditions&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2001</start_date>
  <completion_date type="Actual">November 2001</completion_date>
  <primary_completion_date type="Actual">September 2001</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence based on Cmax and AUC parameters</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Tizanidine HCl 4 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tizanidine HCl Tablets 4 mg, Dr.Reddy's Laboratories Limited</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Zanaflex</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Zanaflex 4 mg Tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tizanidine</intervention_name>
    <description>Tizanidine HCl Tablets 4 mg</description>
    <arm_group_label>Tizanidine HCl 4 mg</arm_group_label>
    <arm_group_label>Zanaflex</arm_group_label>
    <other_name>Zanaflex 4 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects enrolled in this study will be members of the community at large. The&#xD;
             recruitment advertisements may be done using different media (e.g. radio, newspaper,&#xD;
             Anapharm Web site). Subjects must meet all of the following criteria in order to be&#xD;
             included in the study:&#xD;
&#xD;
               -  Subjects will be females and/or males, smokers or non-smokers, 18 years of age&#xD;
                  and older.&#xD;
&#xD;
               -  Female subjects will be post-menopausal or surgically sterilized.&#xD;
&#xD;
          -  Post-menopausal status is defined as absence of menses for the past 12 months.&#xD;
&#xD;
          -  Sterile status is defined as hysterectomy, bilateral oophorectomy or tubal ligation at&#xD;
             least 6 months ago.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects to whom any of the following applies will be excluded from the study:&#xD;
&#xD;
          -  Clinically significant abnormalities found during medical screening.&#xD;
&#xD;
          -  Clinically significant surgery within 4 weeks prior to the administration of the study&#xD;
             medication.&#xD;
&#xD;
        Clinically significant illnesses within 4 weeks of the administration of study medication.&#xD;
&#xD;
          -  History of neuromuscular disease.&#xD;
&#xD;
          -  Abnormal laboratory tests judged clinically significant.&#xD;
&#xD;
          -  ECG abnormalities (clinically significant) or vital sign abnormalities (systolic blood&#xD;
             pressure lower than 100 or over 140 mmHg, or diastolic blood pressure lower than 70 or&#xD;
             over 90; or heart rate less than 60 bpm) at screening.&#xD;
&#xD;
          -  Subjects with BMI ≥ 30.0.&#xD;
&#xD;
          -  History of allergic reactions to tizanidine hydrochloride.&#xD;
&#xD;
          -  Any food allergies, intolerances, restrictions, or special diet which in the opinion&#xD;
             of the medical sub investigator, contraindicates the subject's participation in this&#xD;
             study.&#xD;
&#xD;
          -  Positive urine drug screen at screening.&#xD;
&#xD;
          -  Positive testing for hepatitis B, hepatitis C or HN at screening.&#xD;
&#xD;
          -  Positive urine pregnancy test at screening.&#xD;
&#xD;
          -  Donation of plasma (500 mL) within 7 days or donation or significant loss of whole&#xD;
             blood (500 mL) within 56 days prior to administration of the study medication.&#xD;
&#xD;
          -  History of significant alcohol abuse within six months of the screening visit or any&#xD;
             indication of the regular use of more than two units of alcohol per day (l Unit = 150&#xD;
             mL of wine or 360 mL of beer or 45 mL of alcohol 40%).&#xD;
&#xD;
          -  History of drug abuse or use of illegal drugs: use of soft drugs (such as marijuana,&#xD;
             pot)within 3 months of the screening visit or hard drugs (such as cocaine,&#xD;
             phencyclidine (PCP) and crack) within 1 year of the screening visit.&#xD;
&#xD;
          -  Subjects who have taken prescription medication within 14 days prior to administration&#xD;
             of study medication or over-the-counter products within 7 days prior to administration&#xD;
             of study medication, except for topical products without systemic absorption.&#xD;
&#xD;
          -  Smoking more than 25 cigarettes per day.&#xD;
&#xD;
          -  Use of any drugs known to induce or inhibit hepatic drug metabolism (examples of&#xD;
             inducers: barbiturates, carbamazepine, phenytoin, glucocorticoids, rifampin/rifabutin;&#xD;
             examples of inhibitors: antidepressants, cimetidine, diltiazem, erythromycin,&#xD;
             ketoconazole, MAO inhibitors, neuroleptics, verapamil, quinidine), use of an&#xD;
             investigational drug or participation in an investigational study within 30 days prior&#xD;
             to administration of the study medication.&#xD;
&#xD;
          -  Any reason which, in the opinion of the medical sub investigator, would prevent the&#xD;
             subject from participating in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benoit Girard, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Anapharm</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Anapharm Inc.</name>
      <address>
        <city>Sainte-Foy (Quebec)</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <study_first_submitted>February 10, 2010</study_first_submitted>
  <study_first_submitted_qc>June 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2010</study_first_posted>
  <last_update_submitted>January 12, 2012</last_update_submitted>
  <last_update_submitted_qc>January 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2012</last_update_posted>
  <responsible_party>
    <name_title>Assistant Manager</name_title>
    <organization>Dr. Reddy's Laboratories Limited</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tizanidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

